194 related articles for article (PubMed ID: 19517457)
21. Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma.
Lee I; Byun BH; Lim I; Kim BI; Kong CB; Song WS; Cho WH; Koh JS; Lim SM
Medicine (Baltimore); 2018 Sep; 97(37):e12318. PubMed ID: 30212975
[TBL] [Abstract][Full Text] [Related]
22. Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma.
Huang TL; Liu RS; Chen TH; Chen WY; Hsu HC; Hsu YC
J Chin Med Assoc; 2006 Aug; 69(8):372-6. PubMed ID: 16970273
[TBL] [Abstract][Full Text] [Related]
23. Early response monitoring of neoadjuvant chemotherapy using [
Lee I; Byun BH; Lim I; Kim BI; Choi CW; Koh JS; Song WS; Cho WH; Kong CB; Lim SM
EJNMMI Res; 2020 Jan; 10(1):1. PubMed ID: 31900594
[TBL] [Abstract][Full Text] [Related]
24. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
25. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.
Im HJ; Kim TS; Park SY; Min HS; Kim JH; Kang HG; Park SE; Kwon MM; Yoon JH; Park HJ; Kim SK; Park BK
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):39-49. PubMed ID: 21953008
[TBL] [Abstract][Full Text] [Related]
26. Tumor-to-background ratio to predict response to chemotherapy of osteosarcoma better than standard uptake values.
He JP; Hao Y; Li M; Wang J; Guo FJ
Orthop Surg; 2014 May; 6(2):145-53. PubMed ID: 24890297
[TBL] [Abstract][Full Text] [Related]
27. Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?
Frezza AM; Beale T; Bomanji J; Jay A; Kalavrezos N; Dileo P; Whelan J; Strauss SJ
BMC Cancer; 2014 Jan; 14():23. PubMed ID: 24422949
[TBL] [Abstract][Full Text] [Related]
28. [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer.
Vallböhmer D; Hölscher AH; Schneider PM; Schmidt M; Dietlein M; Bollschweiler E; Baldus S; Alakus H; Brabender J; Metzger R; Mönig SP
J Surg Oncol; 2010 Aug; 102(2):135-40. PubMed ID: 20648583
[TBL] [Abstract][Full Text] [Related]
29. Initial metabolic tumor volume measured by 18F-FDG PET/CT can predict the outcome of osteosarcoma of the extremities.
Byun BH; Kong CB; Park J; Seo Y; Lim I; Choi CW; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Oct; 54(10):1725-32. PubMed ID: 23949909
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.
Gaston LL; Di Bella C; Slavin J; Hicks RJ; Choong PF
Skeletal Radiol; 2011 Aug; 40(8):1007-15. PubMed ID: 21298431
[TBL] [Abstract][Full Text] [Related]
31. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy.
Xiang ZL; Erasmus J; Komaki R; Cox JD; Chang JY
Radiat Oncol; 2012 Aug; 7():144. PubMed ID: 22929048
[TBL] [Abstract][Full Text] [Related]
32. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters.
Denecke T; Hundsdörfer P; Misch D; Steffen IG; Schönberger S; Furth C; Plotkin M; Ruf J; Hautzel H; Stöver B; Kluge R; Bierbach U; Otto S; Beck JF; Franzius C; Henze G; Amthauer H
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1842-53. PubMed ID: 20505933
[TBL] [Abstract][Full Text] [Related]
33. Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.
Raciborska A; Bilska K; Drabko K; Michalak E; Chaber R; Pogorzała M; Połczyńska K; Sobol G; Wieczorek M; Muszyńska-Rosłan K; Rychlowska-Pruszyńska M; Rodriguez-Galindo C; Dziuk M
Clin Transl Oncol; 2016 Feb; 18(2):189-95. PubMed ID: 26250765
[TBL] [Abstract][Full Text] [Related]
34. Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome.
Eary JF; Conrad EU; O'Sullivan J; Hawkins DS; Schuetze SM; O'Sullivan F
J Bone Joint Surg Am; 2014 Jan; 96(2):152-8. PubMed ID: 24430415
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.
Schulte M; Brecht-Krauss D; Werner M; Hartwig E; Sarkar MR; Keppler P; Kotzerke J; Guhlmann A; Delling G; Reske SN
J Nucl Med; 1999 Oct; 40(10):1637-43. PubMed ID: 10520703
[TBL] [Abstract][Full Text] [Related]
36. FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer.
Oku S; Nakagawa K; Momose T; Kumakura Y; Abe A; Watanabe T; Ohtomo K
Ann Nucl Med; 2002 Sep; 16(6):409-16. PubMed ID: 12416580
[TBL] [Abstract][Full Text] [Related]
37. Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer.
Lyshchik A; Higashi T; Nakamoto Y; Fujimoto K; Doi R; Imamura M; Saga T
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):389-97. PubMed ID: 15372209
[TBL] [Abstract][Full Text] [Related]
38. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
[TBL] [Abstract][Full Text] [Related]
39. Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: A meta-analysis.
Li YJ; Dai YL; Cheng YS; Zhang WB; Tu CQ
Eur J Surg Oncol; 2016 Aug; 42(8):1103-14. PubMed ID: 27189833
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma.
Bailly C; Leforestier R; Campion L; Thebaud E; Moreau A; Kraeber-Bodere F; Carlier T; Bodet-Milin C
PLoS One; 2017; 12(8):e0183841. PubMed ID: 28841702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
